
    
      This is a 8-month, multicenter (3 Italian centers), randomized, double-blind,
      placebo-controlled, multicenter, medication-withdrawal study to evaluate the efficacy,
      tolerability, and safety of anakinra in adults and children with idiopathic recurrent
      pericarditis (RP).
    
  